Karo Pharma AB (Karo Pharma AB) COGS-to-Revenue : 0.00 (As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB COGS-to-Revenue?

Karo Pharma AB's Cost of Goods Sold for the three months ended in Jun. 2022 was $0.0 Mil. Its Revenue for the three months ended in Jun. 2022 was $0.0 Mil.

Karo Pharma AB's COGS to Revenue for the three months ended in Jun. 2022 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Karo Pharma AB's Gross Margin % for the three months ended in Jun. 2022 was N/A%.

Karo Pharma AB COGS-to-Revenue Historical Data

The historical data trend for Karo Pharma AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB COGS-to-Revenue Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.48

0.42

0.48

0.45

0.42

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
COGS-to-Revenue	Get a 7-Day Free Trial															0.39	0.44	0.44	0.43	-

Karo Pharma AB COGS-to-Revenue Calculation

Karo Pharma AB's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	138.073	/	325.796
	=	0.42

Karo Pharma AB's COGS to Revenue for the quarter that ended in Jun. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Karo Pharma AB (OTCPK:KARBF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Karo Pharma AB's Gross Margin % for the three months ended in Jun. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Karo Pharma AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019